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Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to 
cancer treatment and following anaesthesia 
 
Abstract 
Introduction: Ondansetron is a 5-HT3 receptor antagonist commonly used as an anti-emetic to 
prevent the nausea and vomiting associated with anti-cancer drugs, cancer radiotherapy, or 
postoperatively.  Recently, the US Food and Drug Administration (FDA) issued a warning for 
ondansetron due to a potential for prolongation of the QT interval of the electrocardiogram (ECG), a 
phenomenon that is associated with an increased risk of the potentially fatal arrhythmia torsade de 
pointes.   
Areas covered: We undertook a review of the cardiac safety of ondansetron.  Our primary sources of 
information were PubMed (with downloading of full articles), and the internet. 
Expert opinion: The dose of ondansetron that the FDA has concerns about is 32 mg iv (or several 
doses that are equivalent to this), which is only used in preventing nausea and vomiting associated 
with cancer chemotherapy.  This suggests that ondansetron may be safe in the lower doses used to 
prevent the nausea and vomiting in radiation treatment or postoperatively.  However, as there is a 
report that a lower dose of ondansetron prolonged the QT interval in healthy volunteers, this needs 
to be clarified by the FDA.  More research needs to be undertaken of the relationship between QT 
prolongation and torsades in order that the FDA can produce clear-cut evidence of pro-arrhythmic 
risk when introducing warnings for this.  
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1. Introduction 
Nausea and vomiting are common complications of cancer chemotherapy and can also occur 
following anaesthesia. Prior to the development of ondansetron, the emesis caused by anti-cancer 
drugs, cancer radiotherapy, or postoperatively was difficult to prevent [1].  Ondansetron is a 
member of the serotonin (5-HT3) receptor antagonist drug class, and this class of drug is good at 
preventing this nausea and vomiting [2,3].   
Ondansetron was granted FDA approval in 1991, and has been widely used, often in combination 
with other antiemetic agents (dexamethasone, aprepitant), and often for the prevention of vomiting 
and nausea caused by high-emetic-risk chemotherapy [4].  However, in late 2011 the US FDA 
released a Safety Communication indicating an ongoing safety review of ondansetron due to a 
potential for prolongation of the QT interval of the electrocardiogram (ECG), a phenomenon that is 
associated with an increased risk of the potentially fatal arrhythmia torsade de pointes [5].  In 
addition, the manufacturer of ondansetron, Zofran, (GlaxoSmithKline) was required to conduct a 
“thorough QT” study to establish the extent to which ondansetron could induce QT interval 
prolongation [5].  On the 12th April, 2012, the FDA notified health care professionals that the 32 mg, 
single intravenous dose of ondansetron would no longer be marketed because of the potential for 
serious cardiac events [6].  At the end of June 2012, a third FDA Safety Communication was released: 
preliminary analysis of the thorough QT study data suggested that intravenous ondansetron 
produces concentration-dependent prolongation of the rate-corrected QT (QTc) interval, with a 
marked prolongation of the QTc interval at the highest tested dose [7].  An independent database of 
drugs with a risk of QT prolongation/torsades de pointes (AZCert.Org) currently lists ondansetron 
amongst drugs that “cause QT prolongation but there is insufficient evidence that they, when used 
as directed in labeling, have a risk of causing TdP” [8]. 
As a result of these FDA warning about ondansetron, we decided to undertake a review of the 
cardiac safety of ondansetron.  As several aspects of the non-cardiac pharmacology of ondansetron 
may affect its clinical cardiac safety, we start by briefly considering the pharmacology with emphasis 
on factors that may influence its cardiac safety (e.g. plasma levels).  Then, we consider both the pre-
clinical and clinical effects of ondansetron on cardiac electrophysiology with particular emphasis on 
changes in ventricular repolarisation, as these may underlie the effects on the QT interval.  Finally, 
we provide an expert opinion which includes attempting to provide both insight into the underlying 
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mechanisms of ECG alterations seen in humans with ondansetron and a context in which to view the 
recent safety concerns voiced by the FDA [5,6,7]. 
2. Non-cardiac pharmacology  
2.1 Pharmacodynamics 
Ondansetron ((RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4(9H)-
one)  was one of the first drugs developed as a selective 5-HT3 receptor antagonis [9].  It is widely 
considered that ondansetron exerts its antiemetic effects in subjects being given highly emetic 
anticancer drugs, by acting as an antagonist at 5-HT3 receptors both centrally in the chemotrigger 
zone and nucleus tractus solitaries, and peripherally  by inhibiting 5-HT binding to vagal afferents in 
the gastrointestinal tract [10].  The following sections have evidence that higher doses of 
ondansetron are required to be effective in preventing nausea and vomiting in cancer chemotherapy 
than the doses required for prophylaxis in radiation treatment or postoperatively.   
2.2 Cancer chemotherapy 
There is some evidence to support a dose-antiemetic relationship with ondansetron.  Thus, during 
multiple dosing with intravenous ondansetron (0.01 to 0.48 mg/kg) of 28 subjects receiving the 
chemotherapeutic agent cisplatin, a correlation between anti-emetic efficacy and AUC ondansetron 
has been suggested [11].  In this study, the trough levels of ondansetron ranged from ~50-200 
ng/ml, 0.25-0.55 µM [11].  In another study, when a high dose of ondansetron (0.18 mg/kg iv) was 
compared with a low dose (0.01 mg/kg iv) in subjects taking high-dose cisplatin, less emesis and 
nausea was observed with the high dose, and both doses were well tolerated [12].  When 
ondansetron 0.15 mg/kg iv every 4 hours x 3, was compared with ondansetron 32 mg iv or 
ondansetron 8 mg iv, in subjects being given anticancer emetic cisplatin, the subjects given 
ondansetron 32 mg had a better outcome (less nausea and more food intake) than with 
ondansetron 8 mg or the standard dose of ondansetron 0.15 mg/kg [13]. A study comparing 
ondansetron 32 mg versus ondansetron 8 mg every 6 hours x 4 in subjects being given cisplatin, also 
showed a better antiemetic profile with the 32 mg than 8 mg [14]. 
With oral ondansetron, 8 mg twice daily was similar effective to 8 mg three times daily in preventing 
emetic episodes in ~60% of 402 subjects taking the moderately emetogenic anticancer drug 
cyclophosphamide [15].  Also, there were no differences in the appetite ratings and nausea scores, 
or adverse effects between ondansetron twice or three times daily [15]. 
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Ondansetron is also used in combination with dexamethasone to prevent emesis with 
chemotherapy.  The rate of complete responses (no emetic episodes) was similar in subjects given 
dexamethasone and ondansetron 8, 24 or 32 mg intravenous, suggesting that the maximum effect 
could be achieved with the lowest dose of ondansetron [16].  However, even with the combination, 
only about half of the subjects had no nausea [16].  Ondansetron 32 mg iv has also be used in 
combination and dexamethasone and the neurokinin-1 antagonist, aprepitant, as the addition of 
aprepitant further reduced the nausea and vomiting in subjects who received cisplatin-based 
chemotherapy [17].  
The most recent consensus recommendations for the prevention of vomiting and nausea following 
high-emetic–risk chemotherapy suggests that ondansetron is one of 5 possible 5-HT3 receptor 
antagonists to be used, and that the oral dose of ondansetron should be 24 mg and the intravenous 
dose 8 mg or 0.15 mg/kg, and that the antagonists should be used in combination with 
dexamethasone and aprepitant [4]. 
2.3 Prophylaxis of radiation nausea and vomiting 
In 111 subjects undergoing fractionated radiotherapy, ondansetron 8 mg bid first day of treatment 
through to 2 days after treatment was compared to placebo, and shown to be effective in 67% of 
subjects, compared to 45% with placebo [18].  With a loading dose of ondansetron of 8 mg before 
radiation therapy, and 8 mg bid for 3 days after the radiation therapy, ondansetron gave complete 
or major control of emesis in 94% of subjects, which was much better than the ~40% control with 
the combination of chlorpromazine and dexamethasone [19]. 
2.4 Post-operatively 
Meta-analysis, of the trials of ondansetron for the prophylaxis of postoperative vomiting in 12,078 
subjects, showed that a 4 mg dose of ondansetron prevented this vomiting in one of 6 subjects, with 
three not vomiting regardless of treatment, and two vomiting despite treatment [20].  A subsequent 
trial in subjects at high risk of postoperative nausea and vomiting showed that ondansetron reduced 
the risk of this by ~25% [21]. 
2.5 Pharmacokinetics 
In determining whether the effects of a drug observed experimentally are likely to occur clinically, it 
is important to determine the plasma levels of drugs in humans, and relate the levels used 
experimentally to those used clinically to determine if the experimental findings are likely to be 
clinically relevant.  After a single intravenous dose of ondansetron 0.15 mg/kg intravenously, the 
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peak maximum concentration in 30 healthy volunteers was 104 ng/ml (0.28 µM), the AUC was 359 
ng/h/ml and the half-life was 3.8 h [22]. 
More recently, it has been reported that after a single intravenous dose of ondansetron 32 mg in 
healthy subjects, there was a peak concentration of ~408 ng/mL (1.11 µM), and the total area under 
the plasma-time curve of 1268.3 ng.h/mL [23]. The levels of ondansetron were not altered by the 
neurokinin-1 receptor antagonist aprepitant, which is used in combination with ondansetron and 
dexamethasone to prevent chemotherapy-induced nausea and vomiting [23]. 
After the effectiveness of intravenous ondansetron as an anti-emetic was established, ondansetron 
was developed for oral administration. After oral and intravenous administration of ondansetron 8 
mg, the maximum plasma concentrations and AUC are higher after intravenous administration, and 
higher in the elderly than young (maximum plasma levels: iv; 83 ng/ml, ~ 0.23 µM, in young and 114 
ng/ml, ~0.31 µM, in old; oral 26 ng/ml, ~0.07 µM, vs 31 ng/ml, ~0.08 µM in old) [24]. 
After the oral administration of ondansetron 8 mg to 20 subjects with cancer, the bioavailability is 
~85%, indicating good absorption from the gastrointestinal tract, and limited first pass metabolism 
[25].  The peak maximum plasma concentration of ondansetron was 381ng/ml (1.04 µM), and AUC 
(381 ng.h/ml) [25], but both of these values had high variation. 
The primary route of ondansetron clearance is liver metabolism, with less than 5% of an iv dose 
excreted unchanged in the kidney [26]. The clearance of ondansetron decreases significantly with 
age being 0.38, 0.32 and 0.26 L/h/kg in young (18-40 years), elderly (60-74) and very aged people 
(>75 years), respectively [22]. The major metabolite, 8-hydroxyondansetron, is equivalent in potency 
as a 5-HT3-receptor antagonist to its parent [22]. As a consequently of liver metabolism, the 
pharmacokinetics of ondansetron are altered by impaired liver function.  Thus, after a single 
intravenous dose of ondansetron 8 mg the peak concentration was 97 ng/ml (0.27 µM) in healthy 
volunteers, and although this was not altered by hepatic impairment, the AUC (ng.h/ml) of 279 was 
progressively increased in mild, moderate and severe hepatic dysfunction [27].  In severe cirrhosis of 
the liver, the clearance is slowed and the half-life extended to 15-20 hours, and thus a maximum 
dose of ondansetron 8 mg total/day is recommended in severe hepatic dysfunction [22]. 
There is evidence that the S(+) and R(-)-isomers are metabolised in different ways, and are therefore 
subject to different genetic effects.  Thus, in subjects given ondansetron 4 mg, prior to general 
anaesthesia, with high (ultrarapid) and no CYP2D6 activity, there are different AUC values of the S(+) 
ondansetron enantiomer of ~150 ng.h/ml and 363ng.h/ml, respectively [28].  After ondansetron 8 
mg, the AUC values were ~154 and 437 mg.h/ml for S(+)-ondansetron in high and no CYP2D6 
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activity, respectively [28]. After the administration of ondansetron 8 mg, but not 4 mg, CYP3A 
expressor status selectively altered R- ondansetron AUC with low and high status giving AUCs of 383 
and 138 mg.h/ml, respectively [28]. In contrast, there was no association between the AUC of R(-)-
ondansetron and CYP2D6 activity or between the AUC of S(+)-ondansetron and CYP3A activity [28].   
Ondansetron is typically administered in tablet or liquid form or intravenously, prior to 
commencement of chemotherapy, radiotherapy, surgery or emergence from anaesthesia.  It can be 
taken orally throughout chemotherapy/radiotherapy, with subsequent discontinuation - sometimes 
with a delay - following the end of treatment.   
3. Pre-clinical data on cardiac electrophysiology 
From the previous section, the peak concentrations of ondansetron observed in humans are about 1 
µM.  In 1991, ondansetron at 1.31 mg/kg iv was reported to have no effect, and at higher doses, 
2.63 and 5.25 mg/kg iv, to prolong the QT interval of anaesthetised dogs by 19 and 28% (~60 and 90 
msec), respectively, without having any effect on the other ECG parameters or blood pressure and 
heart rate [29].  Subsequently, de Lorenzi and colleagues showed that on feline ventricular 
myocytes, and at 1 µM, ondansetron prolonged ventricular APD90 by ~46% (at a stimulation 
frequency of 0.5 Hz), and that the effect of ondansetron was readily reversible on drug washout [30]. 
The effects of ondansetron on APD90 were found to exhibit reverse rate dependence (being 
abolished at a stimulation frequency of 3Hz) [30].  Using voltage-clamp experiments on feline 
ventricular myocytes, they showed that ondansetron inhibited delayed rectifier K+ current, IK, with 
an observed KD of 1.7 ± 1.0 µM [30].  The voltage-dependent activation profile of the current 
affected by the two drugs is consistent with a primary identity as the rapid delayed rectifier K+ 
current, IKr [30].  Ondansetron produced a modest left-ward shift in voltage-dependent activation of 
the current and slowed deactivation of IK tails, producing a ‘cross-over’ phenomenon, features 
consistent with preferential drug interactions with channels in the open (activated) state. The 
inhibition with ondansetron was not strongly voltage-dependent.  
In 2000, Kuryshev et al showed that ondansetron was a weak inhibitor of cloned human Na channels 
(IC50 of 88.5 µM) [31].  The characteristics of the observed INa block were consistent with a 
preferential interaction with Na channels in the inactivated state [31].  These authors also tested the 
effects of ondansetron on recombinant channels encoded by hERG (human ether-à-go-go-related 
gene, alternative nomenclature KCNH2), which pass current similar to native cardiac IKr [32,33].  
Kuryshev et al showed that ondansetron inhibited hERG K+ channel current (IhERG) with an IC50 of 0.81 
µM [31].  Ondansetron also produced an apparent slowing of IhERG deactivation, consistent with the 
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earlier findings on native IK by de Lorenzi et al (1994) and with a preferential interaction between the 
drug and hERG channels in the open state.  Ondansetron at 10 µM was only a weak inhibition of 
KvLQT1+minK (KCNQ1+KCNE1) channels responsible for cardiac IKs [31]. 
Two studies have used Purkinje fibres to explore APD modulation by ondansetron. Purkinje fibres 
offer a sensitive assay for drug-induced effects on AP repolarization, due to their weak repolarization 
reserve and consequent high sensitivity to IKr/hERG blocking drugs [34,35].  In one study of rabbit 
Purkinje fibres driven at 0.2 Hz at 0.1 µM, ondansetron prolonged APD90 by 5.3% whilst at 10 µM a 
prolongation by 76% was observed [36].  The effect of ondansetron showed reverse use-dependence 
i.e. prolongation was smaller at higher frequencies [36]. The same study also assessed droperidol, 
which in addition to prolonging APD produced noticeable triangulation of AP morphology (this did 
not occur for ondansetron) [36].  Early after depolarizations (EADs), which are indicators of potential 
arrhythmia, occurred in 1 of 8 fibres treated with ondansetron at 1 µM, whereas 4 of 7 Purkinje 
fibres produced EADs with this concentration of droperidol and 6 of 7 at a higher concentration of 
10 µM [36].  In a second study of rabbit Purkinje fibres driven at 1 Hz, ondansetron (1-10 µM) 
prolonged APD in a concentration-dependent fashion [37].  Application of the dihydropyridine L-type 
Ca channel inhibitor nifedipine abbreviated ondansetron-induced changes to APD [37]. 
4. Human heart rate  
Ondansetron was approved for use by the FDA in 1991, and there are no publications on the clinical 
effects on the heart prior to this.  In 1993, it was shown that the rapid infusion of ondansetron, 1, 4 
and 8 mg, had no effect on heart rate, blood pressure, oxygen saturation or respiratory rate over a 5 
minute period in 71 female subjects requiring anaesthesia prior to surgery [38]. In 1995, it was 
reported that the intravenous administration of ondansetron 0.15 mg/kg had no effect on heart rate 
or blood pressure in children, two-16 years old, prior to elective tonsillectomy [39]. 
5. Human QT interval  
5.1. Adults 
After intravenous administration of ondansetron, the highest concentration will occur immediately.  
In 1996, in 30 healthy male volunteers, ondansetron (32 mg/kg iv) statistically significantly increased 
the QT interval by 4.8 msec, and also produced a small increase in JT (6.4 msec), but had no 
significant effect on the QTc intervals, but did cause a slight decrease in heart rate (≤ 2 beats/min) 
[40]. In this study, effects were monitored from 15 minutes and changes were usually seen within 4 
hours of drug administration and values returned to baseline within 8 hours [40].  Effects of 
ondansetron occurring in the first 15 minutes after infusion would not have been apparent with this 
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protocol.  In a double-blind study of cancer patients the same year, ondansetron (32 mg i.v.) was 
found to produce “asymptomatic” ECG changes including QT and QTc prolongation by 5.9 and 6.3 
msec after 1-2 hours [41].  Effects of ondansetron on the ECG at earlier time points are not reported 
in this study.   
In a separate study of young healthy subjects, in the following year, after ondansetron 32 mg iv, one 
subject of 13 had an increase in systolic blood pressure from 113 to 163 mm Hg, and there was a QTc 
prolongation from a mean value of 385 to 390 msec, 5 msec, which was significant, whereas in the 
placebo group, the QTc interval increased from 377 to 383 msec, 6 msec, but this was not significant 
[44].  In this study, ondansetron had no effect on the PR or QRS interval [42].  A study of about 700 
subjects with cancer in the same year showed that ondansetron (32 mg iv or 8 mg orally bid) 
prolonged QTc interval in 68 (19%) and QRS in 30 (9%) of the subjects [43].   No details of the degree 
of prolongation were given in this study. 
A 2002 review of the cardiotoxic potential of 5-HT3 receptor antagonist antiemetics, including 
ondansetron, suggested that these agents were the best antiemetic option for subjects receiving 
emetogenic and cardiotoxic chemotherapy, as they had the fewest apparent cardiac effects [44].   
In 2005, ondansetron was studied in 83 subjects being treated for post-operative nausea and 
vomiting in the recovery room, and 21% exhibited prolonged QTc intervals prior to drug 
administration (> 450 msec), possibly due to a perioperative increase, and ondansetron (4 mg i.v.) 
produced QTc prolongation, with maximal prolongation of 20 ± 13 msec at the third minute following 
ondansetron [45].  From their findings, Charbit et al suggested that the perioperative increase in QTc 
interval could be due to hypothermia, or to the anaesthetic, as propofol, thiopental, halogenated 
agents or opioids all interact with the potassium channels involved in repolarization [45]. In 2008, 
the same group shown that ondansetron 4 mg iv prolonged the QTc by 17 msec in healthy volunteers 
[46].  Thus, the magnitude of prolongation of QTc by ondansetron is similar in healthy volunteers or 
in postoperative subjects. 
A separate recent randomized, placebo-controlled, double-blind study comparing differing doses of 
i.v. bolus ondansetron in 136 subjects who had surgical operations, showed there was significant 
and similar QTc prolongations with 4 or 8 mg of ondansetron (8 msec at 10 minutes), but no 
difference between placebo with 1 mg of ondansetron – which was nevertheless effective against 
post-operative nausea and vomiting [47].  Thus, the dosing regimen used may influence propensity 
towards any QTc prolongation.  
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A recent study has investigated effects of intravenous ondansetron 4 mg on the QT interval of 40 
subjects hospitalized with cardiovascular disease (acute coronary syndromes or heart failure), with 
one or more other risk factors for torsades des pointes (hypomagnesaemia, hypokalaemia, 
congenital long QT syndrome, baseline QTc > 500 msec, female gender, old myocardial infarction, 
bradycardia, or receiving a drug that has a risk of causing TdP [48].  Thus 20 subjects were receiving 
either citalopram or ranolazine, 13 venlafaxine and 10 were receiving levofloxacin, erythromycin, or 
methadone [48].  A significant QTc prolongation by 19.3 ± 19 msec was found across the population 
studied when 120 minutes after the administration of ondansetron [48].   The QTc prolongation 
from ~443 msec by 18.3 ± SD = 20 msec and 20.6 ± 20 msec for acute coronary syndromes and heart 
failure, respectively [48].  Forty six percent and 31% subjects with acute coronary syndromes and 
heart failure, respectively, were considered to meet criteria for a prolonged QTc interval [48].  On the 
basis of these findings the authors recommended that patients who are at high risk for torsades who 
receive ondansetron should be monitored by telemetry [48].   
In addition to ondansetron, another drug that is used to prevent emesis, droperidol, has been shown 
to prolong the QTc, which prompted the FDA issue to issue a black box warning about this drug [49]. 
Nevertheless, it has been suggested that ondansetron may be used with droperidol in preventing 
emesis, as having different mechanisms of anti-emesis, their effects may be additive, and this has 
been demonstrated in a clinical trial [50].  In 160 subjects undergoing laparoscopic surgery, there 
was a transient QTc prolongation with ondansetron 4 mg (10 msec after 5 min) and droperidol 1.25 
mg (11 msec)  when given separately, or in combination (13 msec), and the QTc had returned to 
baseline after 2-3 hours [50].  A second combination study, this time using 16 healthy volunteers, 
reported 17 ± 10 msec QTc interval prolongation with ondansetron 4 mg and 25 ± 8 msec QTc 
prolongation with droperidol 1 mg.  In combination, the maximal change to QTc interval was 28 ± 10 
msec, which was significantly longer than that produced by ondansetron alone, but not by 
droperidol alone [51].  
5.2 Children and long QT syndrome 
In 2005, a study in 22 children receiving chemotherapy for acute leukaemia, suggested that 
ondansetron 0.1 mg/kg had no effect on the ECG at 1, 3, 6 and 24 hours [52].  Similarly, in 2006 
Pinarli et al reported no effect of ondansetron 0.15 mg/kg iv on the ECG in 40 children with cancer 
[53].  A recent study of 80 children receiving ondansetron (100 µg/kg), or droperidol (20 µg/kg) or 
both drugs, or saline for elective day-case surgery has noted 10-17 ms prolongation of QT interval 
with ondansetron and droperidol, but this was not significant as there were similar differences in the 
saline/placebo group [54]. This study also measured transmural dispersion of repolarisation (as the 
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interval between the peak and end of the T wave), as this may be a better predictor of torsades des 
points than QTc prolongation, and showed that ondansetron had no effect on this dispersion and no 
arrhythmias were seen [54]. Collectively, these results led the authors to conclude that these drugs 
are normally safe at the doses used [54].  
Long QT syndrome (LQTS) is a disorder or cardiac ion channels resulting in prolongation of the QT 
interval.  Subjects with congenital LQTS are susceptible to torsades de pointes, which may be drug-
induced.  This is exemplified by recent studies of children with previously undiagnosed or overt 
LQTS.  Thus, a recent case report describes rapid onset of polymorphic premature ventricular 
contractions followed by polymorphic ventricular tachycardia after the administration of 0.1 mg/kg 
ondansetron and dimenhydrinate 4 mg/kg to an 11 year old girl undergoing surgery for cyst removal 
[55]. The girl showed a markedly prolonged QT interval of 590 msec, which reduced, but remained 
longer than usual values postoperatively [55]. The authors suggest that the prolongation was due to 
ondansetron, as the histamine H1-receptor antagonist dimenhydrinate had not previously been 
reported to prolong QTc, although other H1-receptor antagonists with similar structures have been 
[55].  The girl was subsequently diagnosed with congenital LQTS [55].    
A separate study of 76 subjects with congenital LQTS, and a mean age of ~13 years, who received a 
total of 114 episodes of anaesthesia found a 2.6% incidence of adverse events/arrhythmias (3 
subjects) [56].  All of the subjects were receiving β-adrenoceptor blocker pre-operatively, and the 
adverse effects occurred during emergence from anaesthesia in close proximity to receipt of both 
reversal (anticholinesterase/anticholinergic) drugs and ondansetron, and were not linked to the 
volatile anaesthetics used [56].  Nathan et al suggest that as the adverse effects occurred during the 
time of increased sympathetic activity, administration anticholinesterase/anticholinergic drugs, and 
ondansetron that a synergism of multiple factors contributed to the adverse event [56].   
6.  Ischemia and arrhythmia 
In 1991, Ballard and colleagues reported seven cases of elderly patients in whom ondansetron 
administration produced chest pain, when being used to prevent emesis with chemotherapy [57]. 
Ballard et al pointed out that this was only an association, and that three of the subjects were taking 
anticancer drugs known to have cardiotoxicity [57].  In 2000, a second case report was published of 
acute myocardial ischaemia in a 60 year old woman who received ondansetron 2 mg iv after a lower 
lobectomy, who developed severe substernal chest pain [58].  On the ECG, she had ST segment 
depression and runs of ventricular tachycardia [58].  Again, there was no sign of myocardial damage 
or cardiac ischaemia after recovery [58].  In a female subject receiving cyclophosphamide for 
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systemic lupus erythrematosus, ondansetron 4 mg iv caused constrictive chest pain and dyspnoea, 
and ischemic changes in the anterior ECG leads, which normalised over time [59].   
Cases of supraventricular tachycardia and bradycardia have also been reported with ondansetron.   
In one case, a 34 year old man under anaesthesia was given metoclopramide 10 mg and then 20 
minutes later ondansetron 2 mg iv, at which time he developed marked bradycardia (50 bpm) and 
then a junctional rhythm of <30 bpm [60]. It is unclear whether or not these changes are attributable 
to ondansetron, however, as metoclopramide has been associated with supraventricular tachycardia 
[61] and with bradyarrhythmias in one subject when co-administered with digoxin [62]. 
One case of fatal ventricular tachycardia associated with ondansetron use has been reported [63].  A 
14 year old girl presenting with vomiting and abdominal pain received 4 mg ondansetron 
intramuscularly together with an antacid. Within 2-3 hours she developed tachycardia and 
circulatory failure; ventricular tachycardia degenerated into ventricular fibrillation, leading to death 
[63].  However, QT interval data were not reported and post-mortem analysis was not possible in 
this case [63]. 
There are also reports of atrial fibrillation with ondansetron.  A 47-year-old female, who was having 
a benign breast lump removed, has also been reported to have atrial fibrillation after her second 
dose of ondansetron 4 mg [64].  In a 51-year-old male, who had elective surgery, after a second dose 
of ondansetron 4 mg iv caused nausea and diaphoresis, and his ECG showed atrial fibrillation and 
inferolateral ST segment elevation and ST segment alterans [65].   
Symptomatic sinus bradycardia with ondansetron 4 mg has been reported in one female, undergoing 
laparoscopic cholecystectomy, who had no signs of cardiac problems when tested on recovery [66]. 
7. Expert opinion 
7.1 Dose and safety of ondansetron 
Higher doses of ondansetron seem to be required to be effective in preventing nausea and vomiting 
in cancer chemotherapy than the doses required for prophylaxis in radiation treatment or 
postoperatively.  The dose of ondansetron that the FDA has concerns about is 32 mg iv (or several 
doses that are equivalent to this), which is only used in preventing nausea and vomiting associated 
with cancer chemotherapy.  This suggests that ondansetron may be safe in the lower doses used to 
prevent the nausea and vomiting in radiation treatment or postoperatively.  
7.2 Published literature and FDA findings 
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Our reading of the published literature has evidence that ondansetron prolongs the QTc interval, but 
there are no major studies specifically reporting torsade de pointes.  However, the FDA has reported 
that torsades occurred in some subjects receiving ondansetron [7].  Although the FDA did not report 
which dose/s of ondansetron caused torsades, they suggest the use of a single 32 mg iv dose of 
ondansetron should be avoided, but that iv doses up to 16 mg and oral doses of 24 mg could still be 
used [7].  The published literature shows that ondansetron prolongs the QTc interval in conditions in 
which the interval is already prolonged, and the FDA confer that subjects who already have a 
prolonged QTc interval due to congenital LQTS, congestive heart failure or who are taking 
concomitant medication that prolong QT interval may be at particular risk [7].  The FDA also 
recommends not using ondansetron in subjects with bradycardias, and correcting electrolyte 
imbalances (e.g. hypokalaemia or hypomagnesaemia) prior to infusing ondansetron [7].   We suggest 
that it would be helpful for the FDA to make available any detailed information in its possession that 
ondansetron induces torsades.  
7.3 QTc prolongation and the International Conference in Harmonization (ICH) 
The testing of all new drugs for QTc interval prolongation is governed by two sets of ICH guidelines: 
ICH S7B for non-clinical evaluation [67] and ICH E14 for clinical evaluation [68].  The ICH S7B 
guidelines recommend both an in vitro IKr assay (on either native IKr or expressed hERG channels) and 
an in vivo QT assay as minimal components of an integrated drug assessment [67], whilst human 
testing must involve “thorough QT” studies that are typically conducted on healthy volunteers 
lacking baseline QTc prolongation [68,69].  No drug can be deemed safe for human use solely on the 
basis of non-clinical data alone [69].  The ICH E14 guidelines also note the importance of drug 
evaluation on human QT interval if a drug (or chemically/pharmacologically related compounds) has 
been associated with QT/QTc prolongation or torsades de point in post-marketing surveillance [68].  
In accord with ICH E14, the FDA requested a thorough QT study, using sufficiently high doses of a 
drug in healthy volunteers and designed to detect small QTc changes (~ 5 msec) [69].  With this 
degree of prolongation, subjects are more prone to develop proarrhythmia [69].  However, it has not 
been proven that this degree of QTc prolongation is necessarily (i.e. deterministically) associated 
with torsades [69].  In this regard, the ICH E14 guidelines both note a lack of consensus in terms of 
upper limits to normal QTc and of changes from baseline and that, whilst the use of conservative 
lower limits might increase the risk of false positives, higher limits risk missing signals of concern 
[67]. The published human cardiac studies of QT interval, reviewed in section 4, clearly establish that 
ondansetron can prolong the QT interval, and there are also case-reports (section 5) that 
ondansetron can cause arrhythmias.   
14 
 
7.4 Parallels with droperidol and QTc prolongations and FDA 
There are parallels between the present situation with ondansetron and the previous situation with 
droperidol, and its prolongation of QTc and the response of the FDA.  Droperidol is a dopamine 
receptor antagonist that has been used as an antiemetic agent, but since 2001 has had a black box 
warning due to cases of QTc prolongation and/or torsades de pointes having been reported [70].  
However, an independent analysis in 2007 of the evidence held by the FDA of 277 cases of adverse 
effects with droperidol, found that 85 of the cases were with the higher doses of droperidol being 
used as an antipsychotic in countries other than the USA [71].  Of the remaining reports, with the 
lower doses of droperidol being used as an antiemetic, many of the reports were found to be 
repeated up to 5 times, and  only 2 described adverse effects with dosages used in the USA [71].  As 
a consequence of this, the black box warning for droperidol remains controversial [72,73,74,75], and 
parallels with the present situation with ondansetron have been made [76].  To avoid a similar 
ongoing controversy with ondansetron, we suggest that the FDA provide the evidence it has 
collected associating ondansetron to torsades for independent analysis as soon as possible, and 
elaborate on their reasoning for the black box warning. 
7.5 Mechanism of QTc prolongation 
From the evidence discussed in sections 3 and 5, it is reasonable to conclude that QTc prolongation 
by ondansetron results from direct repolarization-prolonging effects of the drug.  As for most drugs 
associated with acquired Long QT syndrome [34,77], ondansetron inhibits IKr/hERG [30,31]. In 2003, 
Redfern and colleagues proposed a provisional ‘safety margin’ for hERG blocking drugs of a >30-fold 
difference between hERG IC50 and maximum effective therapeutic concentration (unbound) [78].  
Ondansetron has an IhERG blocking IC50 of 0.81 µM [31] and at plasma levels following intravenous 
administration of high drug doses [19], the cardiac safety margin for ondansetron may be 
unfavourable.  It is nonetheless established that in a clinical setting, only a small proportion of 
patients receiving medications with IKr/IhERG blocking propensity tend to manifest clinically significant 
QTc prolongation and fewer still arrhythmia [76,77].  The extent to which ondansetron produces 
clinically significant QTc prolongation through IKr inhibition is likely therefore to depend both on dose 
and route of administration (with a large dose administered intravenously presumably leading to a 
greater plasma concentration, facilitating IKr block) and the presence of concomitant risk factors.   
     7.6  Mechanisms for other reported ECG changes 
IKr/hERG block may account for QTc prolongation with ondansetron but cannot explain the other ECG 
changes that are occasionally reported with ondansetron (section 6).   The ability of the drug to 
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interact with sodium channels [30] may underpin the observed effects of the drug on the QRS 
complex, particularly under conditions such as ischaemia that may favour drug interactions with 
sodium channels in the inactivated state.  Also, it has been reported that 5-HT3 receptor activation 
may influence coronary arterial tone [79] and ondansetron use has been associated with coronary 
vasospasm [59,65].  Thus, acute ischaemia/ST segment elevation in patients without signs of 
established coronary vascular disease may be attributable to vasoconstrictor actions of ondansetron 
under some conditions.   
7.7 Cardiovascular effects of the isomers 
Ondansetron is a racemic drug, but the effects of the S(+)- and R(-)-isomers on the QT interval have 
not yet been reported in a mainstream journal. However, data associated with a US patent 
supporting stereoselective use of ondansetron for apnoea are suggestive of a smaller effect of R-
ondansetron than of the S-enantiomer or racemic drug form on canine QTc interval [80].  This is an 
important avenue for future investigation, as it is possible that the ability to prolong the QT interval 
is not uniform among the isomers, and that the cardiac safety may also differ between the isomers 
[81]. 
7.8 Palonosetron as an alternative to ondansetron 
As the cardiac safety problems with ondansetron seem to be limited to the iv 32 mg dose used as 
prevention of the nausea and vomiting associated with chemotherapy, it would be advisable to use a 
different anti-emetic agent under these circumstances. Other “etrons” may also have the potential 
to prolong QTc, and the associated cardiac safety issues.  Thus, dolasetron, a second generation 5-
HT3-receptor antagonist, has been shown to prolong QTc, in subjects who are carriers for an allele 
that is associated with prolongation of QTc with 5-HT3-receptor antagonists [82]. However, this is 
not a universal finding for the “etrons”.   
Palonosetron, another second generation 5-HT3 receptor antagonist, has been shown to be superior 
to ondansetron in preventing the nausea and vomiting associated with cancer chemotherapy 
[83,84].  Furthermore, recent studies have shown that palonosetron had no effect on QT interval in 
subjects with cancer [85,86,87].  This suggests that palonosetron is a more effective and safer option 
than ondansetron for preventing nausea and vomiting in subjects with cancer.  Indeed, a recent 
review suggests that palonosetron should be the preferred 5-HT3-receptor antagonist, in 
combination with a NK1- receptor antagonist (e.g. aprepitant) and a dexamethasone, in highly 
emetogenic chemotherapy, and palonosetron with dexamethasone in moderate emetogenic 
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chemotherapy, despite palonosetron 0.25 mg iv costing US $407, compared to ondansetron 24 mg 
~US $4 [88]. 
7.9 Conclusions 
The dose of ondansetron that the FDA has concerns about is 32 mg iv (or several doses that are 
equivalent to this), which is only used in preventing nausea and vomiting associated with cancer 
chemotherapy.  This suggests that ondansetron may be safe in the lower doses used to prevent the 
nausea and vomiting in radiation treatment or postoperatively.  However, as there is a report that 
ondansetron 4 mg iv prolonged the QT interval in health volunteers [46], this needs to be clarified by 
the FDA.  More research needs to be undertaken of the relationship between QT prolongation and 
torsades in order that the FDA can produce clear-cut evidence of pro-arrhythmic risk when 
introducing black box warnings for this.  
As ondansetron is an effective anti-emetic, questions arise regarding what can be done to mitigate 
potential cardiac risk?  Further work is required to establish whether or not single enantiomer 
preparations of ondansetron may in the future offer a viable alternative to the racemic drug.  As the 
FDA have rightly pointed out, the drug should be used with caution in patients with heart failure or 
identified risk factors for QT prolongation and, additionally, electrolyte abnormalities should be 
corrected before use.  For cancer patients who might previously have been treated with 32mg/iv 
ondansetron, or who possess other risk factors for QTc prolongation, palonosetron may offer a safer 
alternative to ondansetron for prevention of nausea and vomiting. 
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